ArticleCureus2026
DNA Methylation Signatures Associated With Smoking Status Across Lung Cancer Subtypes Using The Cancer Genome Atlas (TCGA) Methylation Data.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer remains the leading cause of cancer-related mortality worldwide, with cigarette smoking as its strongest etiologic factor. Beyond genetic mutations, smoking induces epigenetic alterations, particularly DNA methylation, which may differ across lung cancer subtypes and contribute to tumor heterogeneity.
objectiveThe objective of this study was to identify smoking-associated differentially methylated CpG sites (FDR < 0.05) across lung cancer subtypes using The Cancer Genome Atlas (TCGA) 450K methylation data, and to enhance biological interpretation by annotating their genomic context and functional relevance, including associated genes and regulatory features. METHODOLOGY: This retrospective observational study analyzed Illumina HumanMethylation450 BeadChip data from TCGA lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) cohorts. Multivariable linear models within the limma framework assessed differential methylation between smokers and never smokers, adjusting for age, sex, tumor stage, and histology. False discovery rate (FDR) correction was applied.
resultsA total of 771 patients (92 never smokers, 679 smokers) were analyzed. Seven CpG sites were significantly associated with smoking status (FDR < 0.05), with absolute methylation differences (Δβ) ranging from 0.100 to 0.123. Subtype-specific analyses identified eight LUAD-specific and five LUSC-specific smoking-associated CpG sites. LUAD exhibited both hypermethylation and hypomethylation patterns, whereas LUSC showed predominantly smoking-related hypomethylation.
conclusionSmoking is associated with distinct and subtype-specific DNA methylation signatures in lung cancer, underscoring its role in epigenetic tumor modulation and supporting the potential utility of methylation markers in lung cancer stratification and risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.